MTOR and neoplasm: Previous studies have reported alterations in the phosphoinositide 3-kinase (PI3K)/Akt/mTOR signaling pathway, which acts in a proto-oncogene manner and has attracted attention as a target for molecular biomarker-based and targeted tumor therapies [15,33].